Literature DB >> 22927046

Mannose-capped Lipoarabinomannan from Mycobacterium tuberculosis induces soluble tumor necrosis factor receptor production through tumor necrosis factor alpha-converting enzyme activation.

Jillian M Richmond1, Elizabeth R Duffy, Jinhee Lee, Kavon Kaboli, Yun Seong Kim, Daniel G Remick, Hardy Kornfeld, William W Cruikshank.   

Abstract

Primary Mycobacterium tuberculosis infection results in granuloma formation in lung tissue. A granuloma encapsulates mycobacterium-containing cells, thereby preventing dissemination and further infection. Tumor necrosis factor alpha (TNF-α) is a host-protective cytokine during M. tuberculosis infection due to its role in promoting and sustaining granuloma formation. TNF activity is regulated through the production of soluble TNF receptors (sTNFRI and sTNFRII). Therefore, we examined the potential production of endogenous sTNFRs during M. tuberculosis infection. Using the murine model of aerosol M. tuberculosis infection, we determined that levels of sTNFR production were elevated in bronchoalveolar lavage fluid 1 month following infection. An investigation of M. tuberculosis cell wall components identified that the known virulence factor mannose-capped lipoarabinomannan (ManLAM) was sufficient to induce sTNFR production, with sTNFRII being produced preferentially compared with sTNFRI. ManLAM stimulated the release of sTNFRs without TNF production, which corresponded to an increase in TNF-α-converting enzyme (TACE) activity. To determine the relevance of these findings, serum samples from M. tuberculosis-infected patients were tested and found to have an increase in the sTNFRII/sTNFRI ratio. These data identify a mechanism by which M. tuberculosis infection can promote the neutralization of TNF and furthermore suggest the potential use of the sTNFRII/sTNFRI ratio as an indicator of tuberculosis disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22927046      PMCID: PMC3486036          DOI: 10.1128/IAI.00060-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

Review 1.  Roles of lipoarabinomannan in the pathogenesis of tuberculosis.

Authors:  G R Strohmeier; M J Fenton
Journal:  Microbes Infect       Date:  1999-07       Impact factor: 2.700

2.  Development and optimization of cytokine ELISAs using commercial antibody pairs.

Authors:  J A Nemzek; J Siddiqui; D G Remick
Journal:  J Immunol Methods       Date:  2001-09-01       Impact factor: 2.303

Review 3.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Development of antigen detection assay for diagnosis of tuberculosis using sputum samples.

Authors:  L M Pereira Arias-Bouda; L N Nguyen; L M Ho; S Kuijper; H M Jansen; A H Kolk
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

6.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE.

Authors:  C Brou; F Logeat; N Gupta; C Bessia; O LeBail; J R Doedens; A Cumano; P Roux; R A Black; A Israël
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

7.  Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  K H Khoo; J B Tang; D Chatterjee
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

8.  Restraining mycobacteria: role of granulomas in mycobacterial infections.

Authors:  B M Saunders; A M Cooper
Journal:  Immunol Cell Biol       Date:  2000-08       Impact factor: 5.126

9.  Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice.

Authors:  Andre L Moreira; Liana Tsenova; Melles Haile Aman; Linda-Gail Bekker; Sherry Freeman; Bande Mangaliso; Ulf Schröder; Jaishree Jagirdar; William N Rom; Michael G Tovey; Victoria H Freedman; Gilla Kaplan
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

10.  TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.

Authors:  Daniel R Roach; Andrew G D Bean; Caroline Demangel; Malcolm P France; Helen Briscoe; Warwick J Britton
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

View more
  5 in total

1.  Mycobacterium tuberculosis Methyltransferase Rv1515c Can Suppress Host Defense Mechanisms by Modulating Immune Functions Utilizing a Multipronged Mechanism.

Authors:  Anshu Rani; Anwar Alam; Faraz Ahmad; Manjunath P; Abhinav Saurabh; Sheeba Zarin; Dipendra Kumar Mitra; Seyed E Hasnain; Nasreen Z Ehtesham
Journal:  Front Mol Biosci       Date:  2022-06-24

2.  Attenuation of Excess TNF-α Release in Crohn's Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-β Mediated Immunosuppression Through Modulation of TACE Trafficking.

Authors:  Taylor J Louis; Ahmad Qasem; Saleh A Naser
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 3.  Manipulation of the endocytic pathway and phagocyte functions by Mycobacterium tuberculosis lipoarabinomannan.

Authors:  Isabelle Vergne; Martine Gilleron; Jérôme Nigou
Journal:  Front Cell Infect Microbiol       Date:  2015-01-12       Impact factor: 5.293

4.  The iRhom2/ADAM17 Axis Attenuates Bacterial Uptake by Phagocytes in a Cell Autonomous Manner.

Authors:  Anke Seifert; Justyna Wozniak; Stefan Düsterhöft; Petr Kasparek; Radislav Sedlacek; Stephan Dreschers; Thorsten W Orlikowsky; Daniela Yildiz; Andreas Ludwig
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

5.  Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment.

Authors:  Xuejiao Luo; Furong Wu; Jun Ma; Heping Xiao; Haiyan Cui
Journal:  J Int Med Res       Date:  2018-05-13       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.